文献速递肝病

肝脏论坛关于非酒精性脂肪性肝炎治疗试验中合并症管理的提案

A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials.
PubMed 文献 · J Hepatol · 2023-03-29

本文由肝脏论坛委托非酒精性脂肪性肝病相关合并症工作组制定,旨在为NASH治疗试验中候选者和实际参与者的相关合并症管理提供指导。工作组参考科学学会指南并适应NASH试验特点,将管理分为入选前合并症分析与稳定、试验期间合并症管理两部分,提出可接受与最佳控制的概念及随机化前代谢和体重稳定的定义。

要点

  • 肝脏论坛多利益相关方工作组提出NASH治疗试验中合并症管理的指导建议。
  • 管理分两阶段:入选前分析并稳定患者状况,以及试验期间管理合并症。
  • 讨论可接受与最佳控制、随机化前代谢和体重稳定及导入期的利弊。

核心结论

  • 本文提出的建议旨在为临床试验者提供指导,并可在获得更多数据后进一步完善。

研究设计与样本

  • 本文由肝脏论坛委托非酒精性脂肪性肝病相关合并症工作组制定,工作组由学术医学、产业和患者协会的专家组成多利益相关方小组。
  • 工作组在科学学会指南可获取时予以参考,并使其适应NASH试验的特殊情况。

主要发现

  • 本文将行动领域分为两部分:第一,入选试验前对患者状况的分析和稳定;第二,试验进行期间合并症的管理。
  • 对于前者,讨论了合并症可接受控制与最佳控制的概念,定义了随机化前的代谢和体重稳定,并权衡了导入期的利弊。
  • 对于后者,分析了试验期间可能发生的非肝脏合并症变化或急性事件,包括酒精消费的变化,以详细说明何时需要特定干预以及如何根据方法学限制最好地管理合并用药。

局限性

  • 这些建议旨在作为临床试验者的指导,并可在获得更多数据后进一步完善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current document has been developed by the Liver Forum who mandated the NAFLD-Associated Comorbidities Working Group - a multistakeholder group comprised of experts from academic medicine, industry and patient associations - to identify aspects of diverse comorbidities frequently associated with non-alcoholic steatohepatitis (NASH) that can interfere with the conduct of therapeutic trials and, in particular, impact efficacy and safety results. The objective of this paper is to propose guidance for the management of relevant comorbidities in both candidates and actual participants in NASH therapeutic trials. We relied on specific guidelines from scientific societies, when available, but adapted them to the particulars of NASH trials with the aim of addressing multiple interacting requirements such as maintaining patient safety, reaching holistic therapeutic objectives, minimising confounding effects on efficacy and safety of investigational agents and allowing for trial completion. We divided the field of action into: first, analysis and stabilisation of the patient's condition before inclusion in the trial and, second, management of comorbidities during trial conduct. For the former, we discussed the concept of acceptable vs. optimal control of comorbidities, defined metabolic and ponderal stability prior to randomisation and weighed the pros and cons of a run-in period. For the latter, we analysed non-hepatological comorbid conditions for changes or acute events possibly occurring during the trial, including changes in alcohol consumption, in order to detail when specific interventions are necessary and how best to manage concomitant drug intake in line with methodological constraints. These recommendations are intended to act as a guide for clinical trialists and are open to further refinement when additional data become available.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Pais R, Cariou B, Noureddin M, et al. A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials. J Hepatol. 2023. PMID: 37001695. doi:10.1016/j.jhep.2023.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。